Business
NeuroSense Announces Second Quarter 2023 Financial Results and Provides Business Update
ALS Phase 2b PARADIGM Trial Completed Patient EnrollmentTopline results expected in Q-4 2023Cash runway beyond topline clinical study readouts, into Q-2
About this update from Neurosense Therapeutics Ltd.
[{"type":"text","content":"ALS Phase 2b PARADIGM Trial Completed Patient EnrollmentTopline results expected in Q-4 2023Cash runway beyond topline clinical study readouts, into Q-2 2024CAMBRIDGE, Mass., Aug. 16, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (\"NeuroSense\"), a company developing treatments for severe neurodegenerative diseases, today published its financial results for the quarter ended June 30, 2023 and provided a business update.\n\"Throughout this quarter NeuroSense achieved multiple milestones, including the completion of patient enrollment of our Phase 2b ALS study. Results observed from several biomarker studies are promising, especially in that they support our clinical strategy. The findings, along with the data we collect from our Phase 2b study, could inform the optimization of a pivotal Phase 3 study of PrimeC in ALS,\" stated NeuroSense's CEO, Alon Ben-Noon. \"We are well positioned to complete our Phase 2b study and report topline results in Q-4 2023.\"\nBusiness Update\nCapital Raise of $4.5 Million\nIn Q-2 2023, NeuroSense raised $4.5 million in capital and based on our current expense projections is now funded into Q-2 2024, well beyond the expected timing for the release of topline results from the PARADIGM study.\nPhase 2b Amyotrophic Lateral Sclerosis (ALS) PARADIGM Trial Completed Patient Enrollment\nIn Q-2 2023, NeuroSense completed enrollment of its double-blind, placebo-controlled, multi-center Phase 2b clinical trial using a unique upgraded formulation of PrimeC, which is designed to maximize the synergistic effect between the compounds in its combination drug. The clinical trial endpoints include assessment of ALS biomarkers, evaluation of clinical efficacy, and improvement in quality of life to demonstrate an attenuation in disease progression. Elucidation of the mechanism of action of PrimeC utilizing data from the upcoming Phase 2b trial may enable patient stratification and increase the likelihood of success in a pivotal trial. Topline results are expected in Q-4 2023. Significantly, over 96% of participants who completed the trial chose to continue in the study and be treated with PrimeC through a 12-month open-label extension.\nStrategic Scientific Agreement with Biogen\nIn May 2023, NeuroSense announced a collaboration agreement with Biogen to evaluate the impact of PrimeC on neurofilament...